Cargando…

Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices

BACKGROUND: Precision-cut liver slices present different cell types of liver in a physiological context, and they have been explored as effective in vitro model systems to study liver fibrosis. Inducing fibrosis in the liver slices using toxicants like carbon tetrachloride is of less relevance to hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadasivan, Satish Kumar, Siddaraju, Nethra, Khan, Khaiser Mehdi, Vasamsetti, Balamuralikrishna, Kumar, Nimisha R, Haridas, Vibha, Reddy, Madhusudhan B, Baggavalli, Somesh, Oommen, Anup M, Pralhada Rao, Raghavendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296550/
https://www.ncbi.nlm.nih.gov/pubmed/25598841
http://dx.doi.org/10.1186/s13069-014-0017-2
_version_ 1782353007056257024
author Sadasivan, Satish Kumar
Siddaraju, Nethra
Khan, Khaiser Mehdi
Vasamsetti, Balamuralikrishna
Kumar, Nimisha R
Haridas, Vibha
Reddy, Madhusudhan B
Baggavalli, Somesh
Oommen, Anup M
Pralhada Rao, Raghavendra
author_facet Sadasivan, Satish Kumar
Siddaraju, Nethra
Khan, Khaiser Mehdi
Vasamsetti, Balamuralikrishna
Kumar, Nimisha R
Haridas, Vibha
Reddy, Madhusudhan B
Baggavalli, Somesh
Oommen, Anup M
Pralhada Rao, Raghavendra
author_sort Sadasivan, Satish Kumar
collection PubMed
description BACKGROUND: Precision-cut liver slices present different cell types of liver in a physiological context, and they have been explored as effective in vitro model systems to study liver fibrosis. Inducing fibrosis in the liver slices using toxicants like carbon tetrachloride is of less relevance to human disease conditions. Our aim for this study was to establish physiologically relevant conditions in vitro to induce fibrotic phenotypes in the liver slices. RESULTS: Precision-cut liver slices of 150 μm thickness were obtained from female C57BL/6 J mice. The slices were cultured for 24 hours in media containing a cocktail of 10 nM each of TGF-β, PDGF, 5 μM each of lysophosphatidic acid and sphingosine 1 phosphate and 0.2 μg/ml of lipopolysaccharide along with 500 μM of palmitate and were analyzed for triglyceride accumulation, stress and inflammation, myofibroblast activation and extracellular matrix (ECM) accumulation. Incubation with the cocktail resulted in increased triglyceride accumulation, a hallmark of steatosis. The levels of Acta2, a hallmark of myofibroblast activation and the levels of inflammatory genes (IL-6, TNF-α and C-reactive protein) were significantly elevated. In addition, this treatment resulted in increased levels of ECM markers - collagen, lumican and fibronectin. CONCLUSIONS: This study reports the experimental conditions required to induce fibrosis associated with steatohepatitis using physiologically relevant inducers. The system presented here captures various aspects of the fibrosis process like steatosis, inflammation, stellate cell activation and ECM accumulation and serves as a platform to study the liver fibrosis in vitro and to screen small molecules for their antifibrotic activity.
format Online
Article
Text
id pubmed-4296550
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42965502015-01-17 Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices Sadasivan, Satish Kumar Siddaraju, Nethra Khan, Khaiser Mehdi Vasamsetti, Balamuralikrishna Kumar, Nimisha R Haridas, Vibha Reddy, Madhusudhan B Baggavalli, Somesh Oommen, Anup M Pralhada Rao, Raghavendra Fibrogenesis Tissue Repair Research BACKGROUND: Precision-cut liver slices present different cell types of liver in a physiological context, and they have been explored as effective in vitro model systems to study liver fibrosis. Inducing fibrosis in the liver slices using toxicants like carbon tetrachloride is of less relevance to human disease conditions. Our aim for this study was to establish physiologically relevant conditions in vitro to induce fibrotic phenotypes in the liver slices. RESULTS: Precision-cut liver slices of 150 μm thickness were obtained from female C57BL/6 J mice. The slices were cultured for 24 hours in media containing a cocktail of 10 nM each of TGF-β, PDGF, 5 μM each of lysophosphatidic acid and sphingosine 1 phosphate and 0.2 μg/ml of lipopolysaccharide along with 500 μM of palmitate and were analyzed for triglyceride accumulation, stress and inflammation, myofibroblast activation and extracellular matrix (ECM) accumulation. Incubation with the cocktail resulted in increased triglyceride accumulation, a hallmark of steatosis. The levels of Acta2, a hallmark of myofibroblast activation and the levels of inflammatory genes (IL-6, TNF-α and C-reactive protein) were significantly elevated. In addition, this treatment resulted in increased levels of ECM markers - collagen, lumican and fibronectin. CONCLUSIONS: This study reports the experimental conditions required to induce fibrosis associated with steatohepatitis using physiologically relevant inducers. The system presented here captures various aspects of the fibrosis process like steatosis, inflammation, stellate cell activation and ECM accumulation and serves as a platform to study the liver fibrosis in vitro and to screen small molecules for their antifibrotic activity. BioMed Central 2014-12-16 /pmc/articles/PMC4296550/ /pubmed/25598841 http://dx.doi.org/10.1186/s13069-014-0017-2 Text en © Sadasivan et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Sadasivan, Satish Kumar
Siddaraju, Nethra
Khan, Khaiser Mehdi
Vasamsetti, Balamuralikrishna
Kumar, Nimisha R
Haridas, Vibha
Reddy, Madhusudhan B
Baggavalli, Somesh
Oommen, Anup M
Pralhada Rao, Raghavendra
Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices
title Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices
title_full Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices
title_fullStr Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices
title_full_unstemmed Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices
title_short Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices
title_sort developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296550/
https://www.ncbi.nlm.nih.gov/pubmed/25598841
http://dx.doi.org/10.1186/s13069-014-0017-2
work_keys_str_mv AT sadasivansatishkumar developinganinvitroscreeningassayplatformforevaluationofantifibroticdrugsusingprecisioncutliverslices
AT siddarajunethra developinganinvitroscreeningassayplatformforevaluationofantifibroticdrugsusingprecisioncutliverslices
AT khankhaisermehdi developinganinvitroscreeningassayplatformforevaluationofantifibroticdrugsusingprecisioncutliverslices
AT vasamsettibalamuralikrishna developinganinvitroscreeningassayplatformforevaluationofantifibroticdrugsusingprecisioncutliverslices
AT kumarnimishar developinganinvitroscreeningassayplatformforevaluationofantifibroticdrugsusingprecisioncutliverslices
AT haridasvibha developinganinvitroscreeningassayplatformforevaluationofantifibroticdrugsusingprecisioncutliverslices
AT reddymadhusudhanb developinganinvitroscreeningassayplatformforevaluationofantifibroticdrugsusingprecisioncutliverslices
AT baggavallisomesh developinganinvitroscreeningassayplatformforevaluationofantifibroticdrugsusingprecisioncutliverslices
AT oommenanupm developinganinvitroscreeningassayplatformforevaluationofantifibroticdrugsusingprecisioncutliverslices
AT pralhadaraoraghavendra developinganinvitroscreeningassayplatformforevaluationofantifibroticdrugsusingprecisioncutliverslices